Navigation Links
Meso Scale Discovery Launches V-PLEX™ Multiplex Biomarker Immunoassays
Date:9/11/2013

Rockville, MD (PRWEB) September 11, 2013

There is a significant unmet need for accurate and precise biomarker tests for clinical trials, drug development and medical research. V-PLEX simultaneously measures multiple biomarkers using assays that are grouped into panels for optimal and consistent performance. The V-PLEX immunoassay menu focuses on emerging biomarkers that are generally not available on traditional diagnostics platforms, giving researchers access to new types of tests.

“We’re very excited that the life science and clinical research community will now have access to new biomarker tests through V-PLEX,” said Jacob Wohlstadter, President and CEO. “The lack of validated tests for biomarkers has challenged pharmaceutical companies and been a major limitation for important medical research. Together with our recently launched QuickPlexSQ 120 instrument, V-PLEX offers unprecedented access to high-quality immunoassays in a flexible and affordable format.”

Validated tests enable long-term programs like clinical trials and epidemiological studies by providing sustainable, reliable measurements of clinically significant markers. These tests have defined, rigorous specifications for analytical performance, and each new lot passes strict requirements before release. Results from validated tests are viewed with greater confidence and are often required for regulatory approvals.

“The practical implications of V-PLEX are significant, particularly for laboratories and CROs that run biomarker tests as their primary business” said Dr. James Wilbur, General Manager. “In the absence of available tests, these laboratories must bear the burden of developing their own tests and conducting formal validations, which is simply unaffordable for many markers. With V-PLEX, these laboratories can now offer a wide menu of biomarkers in a fully-validated format, and, through the use of V-PLEX panels, reduce their labor, costs and sample consumption even further.”

V-PLEX immunoassays, using MSD’s proprietary electrochemiluminescence (ECL) MULTI-ARRAY® technology, are developed under rigorous design control and are fully validated according to “Fit for Purpose” principles. They are compatible with either MSD’s SECTOR® or QuickPlex instrument lines. The initial menu of V-PLEX immunoassays includes the most important cytokines, chemokines, and Alzheimer’s disease biomarkers.

For more information on V-PLEX immunoassays, call Customer Service at 1-240-314-2795; email customerservice@mesoscale.com; or visit http://www.mesoscale.com/V-PLEX.

Read the full story at http://www.prweb.com/releases/immunoassay/news/prweb11109813.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. CPUsage Launches Massive Scale Cloud Computing Platform at TechCrunch Disrupt
2. Breakthrough in sensing at the nanoscale
3. LIMS 24/7 and Ayrris: Big-Data Lab Management for Production-Scale NGS
4. Broad-scale genome tinkering with help of an RNA guide
5. Meso Scale Discovery Launches New Quickplex™ SQ 120 Multiplex Immunoassay Instrument
6. Unisense FertiliTech to Present Large Scale Time-lapse Data Analysis to Improve IVF Treatment
7. Cross-Cultural Qualitative Research for Simultaneous Scale Development, New Life Science Webinar Hosted by Xtalks
8. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
9. Study led by GW professor provides better understanding of waters freezing behavior at nanoscale
10. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
11. CIC nanoGUNE launches Simune, an atomic-scale simulations service for companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017  Asterias Biotherapeutics, Inc. ... field of regenerative medicine, today announced positive efficacy ... clinical trial that showed additional motor function improvement ... million AST-OPC1 cells in AIS-A patients with complete ... of upper extremity motor function is critically important ...
(Date:1/24/2017)... Switerland (PRWEB) , ... January 24, 2017 , ... ... first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of histidine ... which are available in a range of concentrations from six different malaria strains, ...
(Date:1/24/2017)... , ... January 23, 2017 , ... Oklahoma City based ... newest client for the firm’s PERFEQTA software and legacy product QC Manager 2.0. ... the dynamic team at CJBC and thrilled that they have decided to implement PERFEQTA ...
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... into an underwriting agreement with Rodman & Renshaw, a ... as sole book running manager and representative of several underwriters, ... a firm commitment basis a minimum of 2,105,264 shares ... to purchase a minimum of 1,052,632 shares of common ...
Breaking Biology Technology:
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):